DDInter1325 DDInter927
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Ofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Ofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Ofloxacin {u} (Compound) binds {v} (Gene) SLC22A4
Ofloxacin {u} (Compound) upregulates {v} (Gene) SELL
Ofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Ofloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Ofloxacin {u} (Compound) downregulates {v} (Gene) RB1
Ofloxacin {u} (Compound) causes {v} (Side Effect) Petechiae
Ofloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pentostatin
Ofloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Procarbazine
Ofloxacin (Compound) resembles Enoxacin (Compound)
Ofloxacin (Compound) resembles Levofloxacin (Compound)
Ofloxacin (Compound) binds SLC22A4 (Gene)
Ofloxacin (Compound) upregulates SELL (Gene)
Ofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Ofloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Ofloxacin (Compound) downregulates RB1 (Gene)
Ofloxacin (Compound) causes Petechiae (Side Effect)
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine